BD-pTau217 is a brain-derived phosphorylated tau protein isoform that serves as a highly specific biomarker for neurodegenerative disease. Tau proteins are distributed throughout the body, but only a fraction found in blood originates from the brain, with the majority secreted by peripheral organs. Elevated levels of BD-pTau217 in cerebrospinal fluid (CSF) are a hallmark of Alzheimer’s Disease (AD), while increased blood pTau217—primarily from peripheral sources is associated with other neurodegenerative diseases.
The NULISAqpcr BD-pTau217 Assay precisely detects brain-derived pTau217 in either blood or cerebral spinal fluid using only 10 µL* of biological sample. The analytical performance of the NULISAqpcr BD-pTau217 Assay
has been rigorously validated to ensure the highest level of confidence in your results.
Specific detection of brain-derived pTau217 for neurodegenerative disease insights. In neurodegenerative conditions marked by Tau accumulation, protein sources may originate from either brain or peripheral tissues. For Alzheimer’s disease, when detecting pTau217 from blood or plasma it is critical to distinctly detect brain originated pTau217 versus that originated from peripheral tissues.
Precise Quantitation
Absolute quantitation of plasma-based brain-derived pTau217.
CNS Specificity
Uniquely specific to the low molecular weight pTau217 isoform originating from the central nervous system.
Clinical Research Utility
Supports clinical research and longitudinal studies with CV <10%.
Automated Workflow
Fully automated workflows with under 30 minutes hands-on time using the ARGO HT system.
Flexible Sample Collection
Established protocols for blood, plasma, and dried blood spot collection devices.
Detect elevated levels of brain-derived pTau217 in plasma from Alzheimer’s disease samples.
A 7-point standard curve enables absolute quantitation.
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.
